Similar drugsTo uncover
Dosage form: & nbsplyophilizate for the preparation of a solution for intravenous administration
Composition:

Per 1 bottle:

active substances: Piperacillin sodium (in terms of piperacillin) 2085.0 (2000.0) mg / 4170.0 (4000.0) mg, sodium tazobactam (expressed as tazobactam) 268.3 (250.0) mg / 536.6 ( 500.0) mg.

Description:

Ba white or almost white powder or a porous mass.

Pharmacotherapeutic group:antibiotic-penicillin semisynthetic + beta-lactamase inhibitor
ATX: & nbsp
  • Combinations of penicillins (including those with beta-lactamase inhibitors)
  • Pharmacodynamics:

    Piperacillin It is a semisynthetic antibiotic with broad spectrum bactericidal action, exhibiting activity against Gram negative and many Gram-positive aerobic and anaerobic bacteria. Inhibits the synthesis of the membrane of the cell wall of the microorganism.

    Tazobactam - triazolmetilpenitsillanovoy acid sulfone derivative, it is a potent inhibitor of many beta-lactamase (including plasmid and chromosomal beta-lactamase), which often cause resistance to penicillins and cephalosporins, including to cephalosporins of the third generation. The presence of tazobactam in the composition of the combined preparation Piperacillin-tazobactam-Teva enhances antimicrobialactivity and expands the spectrum of action of piperacillin due to the inclusion in it of many bacteria-producers of beta-lactamase, which are usually resistant to piperacillin and other beta-lactam antibiotics. Thus, the drug Piperacillin-Tazobactam-Teva combines the properties of a broad-spectrum antibiotic and a beta-lactamase inhibitor.

    Sensitive microorganisms:

    - aerobic gram-negative microorganisms: Producing and non-producing beta-lactamase strains Acinetobacter spp., Campylobacter spp., Enterobacter spp. (at Tom number of Enterobacter cloacae, Enterobacter aerogenes), Escherichia coli, Citrobacter spp. (at Tom number of Citrobacter freundii, Citrobacter diversus), Gardnerella vaginalis, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella spp. (at Tom number of Klebsiella oxytoca, Klebsiella pneumoniae), Moraxella spp. (including Branhamella catarrhalis), Morganella morganii, Neisseria gonorrhoeae, Neisseria meningitidis, Pasteurella multocida, Plesiomonas shigelloides, Proteus vulgaris, Proteus mirabilis, Providenda rettgeri, Providenda stuartii, Pseudomonas aeruginosa and others Pseudomonas spp. (at Tom number of Pseudomonas cepacia, Pseudomonas fluorescens), Salmonella spp., Serratia spp. (including Serratia marcescens, Serratia liquefaciens), Shigella spp., Xanthomonas maltophilia, Yersinia spp .;

    - aerobic Gram-positive microorganisms: Producing and non-producing beta-lactamase strains Enterococcus spp. (including Enterococcus faecalis, Enterococcus faecium), Listeria monocytogenes, Nocardia spp., Staphylococcus aureus (sensitive to methicillin), Staphylococcus saprophyticus, Staphylococcus epidermidis (coagulase negative), Streptococcus spp. (including Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus bovis, Streptococcus agalacliae, Streptococcus spp. groups viridans subgroup C and G);

    - anaerobic microorganisms: Producing and non-producing beta-lactamase strains Actynomyces spp., Bacteroides spp. (Bacteroides bivius, Bacteroides disiens, Bacteroides capillosus, Bacteroides melaninogenicus, Bacteroides oralis), subgroups Bacteroides fragilis (Bacteroides fragilis, Bacteroides vulgatus, Bacteroides distasonis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides asaccharolyticus), Clostridium spp. (at t. h. Clostridium difficile, Clostridium perfringens), Eubacterium spp., Fusobacterium spp., Peptostreptococcus spp., Veilonella spp.

    Minimum inhibitory concentrations

    Name of microorganisms

    Sensitive

    Moderately sensitive

    Resistant

    Enterobacteriaceae

    < 16 mg / l

    32-64 mg / l

    > 128 mg / l

    Pseudomonas spp.

    < 64 mg / l

    -

    > 128 mg / l

    Staphylococcus spp.

    < 8 mg / l

    -

    > 16 mg / l

    * Streptococcus spp.

    <1 mg / l

    -

    > 2 mg / l

    Anaerobes

    < 32 mg / l

    64 mg / l

    > 128 mg / l

    * The prevalence of acquired resistance may vary in different geographic areas and time periods for individual species.

    Pharmacokinetics:

    The maximum concentration (CmOh) piperacillin and tazobactam in blood plasma is achieved immediately after the end of intravenous (IV) administration of the drug. When piperacillin / tazobactam was administered at a dose of 2.25 g and 4.5 g FROMmOh piperacillin is 134 μg / ml and 298 μg / ml, respectively, and tazobactam is 15.24 μg / ml and 34 μg / ml, respectively.

    At plasma concentrations above 100 μg / ml piperacillin binds to blood proteins by 21%, and tazobactam by 23%.

    Piperacillin and tazobactam well penetrate into body fluids and tissues, including the intestinal mucosa, gall bladder, lungs, bile, bone tissue, uterus, ovaries, fallopian tubes.The average concentration of piperacillin / tazobactam in tissues is 50-100% of the plasma concentration. Also piperacillin / tazobactam is penetrated through the placenta, into breast milk and slightly through the blood-brain barrier.

    Piperacillin is metabolized to a weakly active desethylate metabolite, tazobactam is metabolized to an inactive metabolite.

    Piperacillin / tazobactam is excreted by the kidneys through glomerular filtration and tubular secretion. The amount of unchanged piperacillin in urine is 68% of the dose. 80% of the initial dose of tazobactam is excreted by the kidneys, both in unchanged form and in the form of a metabolite. The remainder of piperacillin / tazobactam, both in unchanged form and in the form of metabolites, is excreted with bile.

    Half-life (T1/2) piperacillin / tazobactam is 0.7 to 1.2 hours and does not depend on the dose administered, nor on the duration of administration of piperacillin / tazobactam. With a decrease in the clearance of creatinine (CC), Tc of piperacillin / tazobactam increases.

    The pharmacokinetics of piperacillin does not change with simultaneous administration with tazobactam, but it is considered that piperacillin extends T1/2 tazobactam.

    In patients with impaired renal function (CC less than 20 ml / min) T1/2 piperacillin and tazobactam increases 2 and 4 times, respectively, compared with patients with normal renal function.

    In hemodialysis, 30% to 50% of piperacillin / tazobactam and an additional 5% of tazobactam are metabolized. With peritoneal dialysis, 6% piperacillin and 21% tazobactam are excreted, in addition 16% of the tazobactam is excreted as a metabolite.

    T1/2 piperacillin and tazobactam in patients with cirrhosis increases by 25% and 18%, respectively.

    Indications:

    The drug is used to treat systemic and / or local bacterial infections caused by microorganisms sensitive to piperacillin / tazobactam.

    Adults, including elderly patients, and children over 12 years of age:

    - infections of the lower respiratory tract;

    - urinary tract infections (complicated and uncomplicated);

    - intra-abdominal infections;

    - infections of the skin and soft tissues;

    - septicemia;

    - bacterial infections in patients with neutropenia (in combination with aminoglycosides);

    - infection of bones and joints;

    - gynecological infections;

    - polymicrobial infections caused by Gram-positive / Gram-negative aerobic and anaerobic microorganisms.

    Children aged 2-12 years:

    - intra-abdominal infections;

    - bacterial infections against the background of concomitant neutropenia (in combination with aminoglycosides).

    Contraindications:

    Hypersensitivity to piperacillin / tazobactam, drug components, other beta-lactam antibiotics or beta-lactamase inhibitors; age to 2 years (efficacy and safety not studied).

    Carefully:

    Severe bleeding (including history), cystic fibrosis (increased risk of hyperthermia and skin rash), pseudomembranous colitis, renal failure, hypokalemia, hemodialysis patients, simultaneous use of high doses of anticoagulants, pregnancy, the period of breastfeeding.

    Pregnancy and lactation:

    Piperacillin and tazobactam penetrate the placenta, although they do not have embryotoxicity or teratogenic effects. The use of the drug Piperacillin-Tazobactam-Teva during pregnancy is permissible only for "vital" indications, when the expected benefit for the mother exceeds the possible risk to the fetus.

    The drug Piperacillin-Tazobactam-Teva during breastfeeding should be used only if the expected benefit from the use for the mother exceeds the possible risk to the child,or during the treatment should stop breastfeeding.

    Dosing and Administration:

    The drug Piperacillin-Tazobactam-Teva should be administered in the form of IV injections slowly for 3-5 minutes or infusions for 20-30 minutes.

    The duration of treatment with Piperacillin-Tazobactam-Teva depends on the dynamics of the patient's condition and the results of bacteriological tests. The recommended duration of therapy is from 5 to 14 days. The drug should be used for at least 48 hours after the disappearance of all clinical symptoms of the disease.

    Adults and children over 12 years of age:

    The recommended dose is 4.5 g (4 g piperacillin / 0.5 g tazobactam) every 8 hours. The average daily dose depends on the severity and localization of the infectious process and can vary from 2.25 g (2 g piperacillin / 0.25 g tazobactam) to 4.5 g (4 g piperacillin / 0.5 g tazobactam) every 6-8 h .

    In elderly patients correction of the dose is not required.

    In adults and children with a body weight of more than 50 kg and kidney failure dosage adjustment depends on QC. With QC more than 40 ml / min dose adjustment is not required. At CC 20-40 ml / min - 12 g / 1.5 g / day (4 g piperacillin / 0.5 g tazobactam every 8 hours). At CC less than 20 ml / min - 8 g / 1 g / day (4 g piperacillin / 0.5 g tazobactam every 12 hours).

    Patients in need of hemodialysis, the maximum daily dose is 9 g / day (8 g piperacillin / 1 g tazobactam / day). Since during the hemodialysis 30-50% of piperacillin is washed out after 4 hours, it is necessary to additionally inject 2.25 g (2 g piperacillin / 0.25 g tazobactam) after each hemodialysis session.

    Children aged 2-12 years:

    Intra-abdominal infections

    In children with a body weight of less than 40 kg and normal kidney function the recommended daily dose is 112.5 mg / kg (100 mg / kg piperacillin / 12.5 mg / kg tazobactam) every 8 hours, no more than 4.5 g (4 g piperacillin / 0.5 g tazobactam) per administration. Duration of therapy is 5-14 days.

    In children with a body weight of more than 40 kg and normal kidney function apply the same dose as in adults, i.e. 4.5 g (4 g piperacillin / 0.5 g tazobactam) every 8 h.

    Bacterial infections on the background of concomitant neutropenia (in combination with aminoglycosides)

    In children weighing less than 50 kg and normal kidney function the recommended daily dose of the drug is 90 mg / kg (80 mg / kg piperacillin / 10 mg / kg tazobactam) every 6 hours, no more than 4.5 g (4 g piperacillin / 0.5 g tazobactam) for administration, in combination with aminoglycosides .

    In children with a body weight of more than 50 kg and normal kidney function apply the same dose as in adults, and inject it in combination with aminoglycosides.

    In children with kidney failure the pharmacokinetics of piperacillin / tazobactam have not been studied.

    In children with a body weight of less than 50 kg and kidney failure dosage adjustment depends on QC. At CC, more than 50 ml / min - 112.5 mg / kg (100 mg / kg piperacillin / 12.5 mg / kg tazobactam) every 8 hours. At CC less than 50 ml / min - 78.75 mg / kg (70 mg / kg piperacillin (8.75 mg / kg tazobactam) every 8 hours. This dose change is indicative.

    Each patient should be monitored for the timely detection of signs of an overdose. It is necessary to adjust the dose of the drug and the interval between the administration of the next dose accordingly.

    For children weighing less than 50 kg, in need of hemodialysis, the recommended dose is 45 mg / kg (40 mg / kg piperacillin / 5 mg / kg tazobactam) every 8 hours.

    In patients with impaired liver function correction of the dose is not required.

    Preparation of solution for intravenous administration

    The drug Piperacillin-Tazobactam-Teva is used only for IV administration. The preparation is dissolved with one of the solvents compatible with the preparation Piperacillin-Tazobactam-Teva in accordance with the volume indicated in the table.The vial is rotated in a circular motion until the content is completely dissolved (with constant rotation, usually for 5-10 min). The resulting solution is a colorless or pale yellow liquid.

    Dosage / vial of the drug Piperacillin-Tazobactam-Teva

    Volume of solvent (ml)

    2.25 g

    (2 g piperacillin / 0.25 g tazobactam)

    10

    4.5 g

    (4 g piperacillin / 0.5 g tazobactam)

    20

    Solvents compatible with the drug Piperacillin-Tazobactam-Teva: 0.9% solution of sodium chloride; sterile water for injections; 5% dextrose solution.

    Then, to further dilute the drug to the required volume for intravenous infusion (for example, from 50 ml to 150 ml), the prepared solution is diluted with one of the following compatible solutions: 0.9% sodium chloride solution; sterile water for injections (the maximum recommended volume is 50 ml); 5% dextrose solution.

    The prepared solution should be stored at a temperature of 2 to 8 ° C not more than 48 hours. If a "flake", a crystal is found in a prepared solution, including a change in its color or any other indication of pharmaceutical interaction or contamination, infusion should be stopped immediately.

    To reduce the risk of microbial contamination of the drug Piperacillin-Tazobactam-Teva for intravenous administration, it is recommended that it be prepared immediately before infusion.

    Unused for 48 hours, the prepared solution is not recommended for use and should be disposed of in accordance with local requirements.

    Side effects:

    The frequency of side effects is classified according to the recommendations of the World Health Organization: very often - not less than 10%; often - not less than 1%, but less than 10%; infrequently - not less than 0,1%, but less than 1%; rarely - not less than 0.01%, but less than 0.1%; very rarely - less than 0.01%, including single messages.

    Infections and infestations: infrequently - candidiasis, the development of superinfection.

    From the hemopoietic and lymphatic systems: infrequently - leukopenia, neutropenia, thrombocytopenia; rarely - anemia, bleeding (hemorrhagic purpura, epistaxis, increased coagulation time), eosinophilia, hemolytic anemia; very rarely - agranulocytosis, positive Coombs test, pancytopenia, lengthening of partial thromboplastin time, prolongation of prothrombin time, thrombocytosis.

    From the immune system: infrequently - hypersensitivity reactions; rarely anaphylactic / anaphylactoid reactions (including anaphylactic shock).

    From the side of metabolism: very rarely - a decrease in the concentration of serum albumin, hypoglycemia, a decrease in the concentration of total protein in the blood plasma, hypokalemia.

    From the nervous system: infrequently - headache, insomnia; rarely - muscle weakness, hallucinations, convulsions, dizziness.

    From the cardiovascular system: infrequently - lowering blood pressure, phlebitis, thrombophlebitis; rarely - "tides".

    From the gastrointestinal tract: often - diarrhea, nausea, vomiting; infrequently - constipation, dyspepsia, stomatitis; rarely - dryness of the oral mucosa, abdominal pain, pseudomembranous colitis.

    From the liver and bile ducts: infrequently - increased activity "hepatic" transaminases in the serum, jaundice; rarely - increased activity of alkaline phosphatase and gamma-glutamyltransferase, increased bilirubin concentration in blood plasma, hepatitis.

    From the skin and subcutaneous tissues: often - a rash, infrequently - itching, hives, erythema; rarely - bullous dermatitis, multiforme exudative erythema, hyperhidrosis; very rarely - Stevens-Johnson syndrome, toxic epidermal necrolysis.

    From the side of the musculoskeletal system and connective tissue: rarely - arthralgia, muscle pain.

    From the urinary system: infrequently - an increase in the concentration of creatinine in the blood plasma; rarely - interstitial nephritis, kidney failure; very rarely - an increase in the concentration of urea in the blood plasma.

    General disorders and disorders at the site of administration: infrequently - fever, reactions at the injection site (pain and hyperemia at the injection site); rarely - chills, fatigue, swelling.

    Overdose:

    Symptoms: nausea, vomiting, diarrhea, convulsions, especially in patients with renal insufficiency.

    Treatment: the specific antidote is unknown. It is necessary to constantly monitor the patient, control vital signs, symptomatic therapy. Hemodialysis is effective. With the development of seizures, anticonvulsants should be used (diazepam, barbiturates).

    Interaction:

    Simultaneous administration of probenecid and the drug Piperacillin-Tazobactam-Teva increases Tc and decreases the renal clearance of both piperacillin and tazobactam without changing their plasma concentrations.

    Piperacillin alone or in combination with tazobactam does not have a clinically significant effect on the pharmacokinetics of tobramycin in patients with both normal renal function and with mild or moderate impairment of their function.

    Clinically significant interaction with simultaneous use of vancomycin with the drug Piperacillin-Tazobactam-Teva was not detected.

    With simultaneous administration with high doses of heparin, the use of anticoagulant means of indirect action and other drugs that affect the blood clotting system and / or platelet structure, it is necessary to more often monitor the parameters of blood coagulability.

    Simultaneous use of piperacillin and vecuronium bromide results in an increase in the time of neuromuscular blockade caused by the muscle relaxant.

    Piperacillin reduces the excretion of methotrexate (in order to avoid a toxic effect it is necessary to monitor the concentration of methotrexate in the blood plasma).

    The drug is pharmaceutically incompatible with aminoglycosides, Ringer's lactate solution, blood, blood substitutes or hydrolysates of albumin.

    When mixing solutions of the drug Piperacillin-Tazobactam-Teva and aminoglycosides, their inactivation is possible, therefore it is recommended that these preparations be administered separately. In situations where simultaneous use is preferred, solutions of the drug Piperacillin-Tazobactam-Teva and aminoglycosides should be prepared separately.

    The drug Piperacillin-Tazobactam-Teva should not be used concomitantly with solutions containing sodium hydrogen carbonate.

    Special instructions:

    Before starting treatment with Piperacillin-Tazobactam-Teva, the patient should be interviewed in detail in order to identify possible reactions of hypersensitivity in the anamnesis, incl. associated with the use of penicillins or cephalosporins. It is possible to develop cross-reactivity hypersensitivity reactions with other beta-lactam antibiotics, especially in patients with multiple allergies. When developing a severe hypersensitivity reaction (anaphylaxis), the drug should be immediately discontinued and emergency measures, including epinephrine, should be applied.

    If persistent diarrhea occurs, the possibility of developing pseudomembranous colitis should be taken into account both during and after therapy. In these cases, therapy with Piperacillin-Tazobactam-Teva should be stopped immediately and appropriate treatment (for example, vancomycin, metronidazole for oral administration). Preparations that inhibit peristalsis are contraindicated.

    When therapy with the drug Piperacillin-Tazobactam-Teva, especially prolonged, it is possible to develop leukopenia and neutropenia, therefore it is necessary to periodically monitor the peripheral blood.

    Despite the low toxicity of the drug, long-term treatment should regularly monitor the peripheral blood and assess the function of the kidneys and liver.

    In a number of cases (most often in patients with renal insufficiency), there may be increased bleeding and a concomitant change in the laboratory parameters of the blood coagulation system (clotting time, platelet aggregation and prothrombin time). When there is evidence of bleeding, the antibiotic should be discontinued and appropriate therapy applied.

    The preparation contains 0.054% sodium, which should be taken into account in patients on a controlled sodium diet.

    With prolonged use of the drug Piperacillin-Tazobactam-Teva, it is possible to develop microbial resistance, as well as the development of fungal infection.

    When treated with Piperacillin-Tazobactam-Teva, the risk of developing fever and rash increases in patients with cystic fibrosis.

    In patients with hypokalemia or receiving drugs that promote the excretion of potassium, during the period of treatment with the drug Piperacillin-Tazobactam-Teva hypokalemia may develop (regular monitoring of the electrolyte content in blood serum).

    When using doses higher than those recommended, there may be increased neuromuscular excitability and convulsions, as with other penicillins (convulsions, impaired consciousness, myoclonus).

    It is necessary to consider the possibility of the emergence of resistant microorganisms, which can cause the development of superinfection, especially with a long course of treatment.

    During the application of the drug Piperacillin-Tazobactam-Teva, a false-positive result of a test for glucose in the urine is possible,based on the reduction of copper ions. Therefore, it is recommended to carry out a test based on the enzymatic oxidation of glucose.

    Effect on the ability to drive transp. cf. and fur:

    The use of the drug Piperacillin-Tazobactam-Teva does not affect the ability to drive vehicles and engage in other potentially hazardous activities requiring increased concentration and speed of psychomotor reactions.

    With the development of side effects, such as dizziness, hallucinations, convulsions, it is not recommended to engage in potentially hazardous activities.

    Form release / dosage:

    Lyophilizate for the preparation of a solution for intravenous administration, 2.0 g + 0.25 g and 4.0 g + 0.5 g.

    Packaging:

    By 2 g of piperacillin and 0.25 g of tazobactam or 4 g of piperacillin and 0.5 g of tazobactam into clear glass vials of the type II with bromobutyl plugs, aluminum caps equipped with a protective cap-insert from colored polypropylene.

    1 bottle per pack of cardboard along with instructions for use.

    Storage conditions:

    Store at a temperature of no higher than 25 ° C, in a place protected from light.

    The prepared solution should be stored at a temperature of 2 to 8 ° C not more than 48 hours.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the expiry date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-001658
    Date of registration:17.04.2012
    Date of cancellation:2017-04-17
    The owner of the registration certificate:Teva Pharmaceutical Enterprises Co., Ltd.Teva Pharmaceutical Enterprises Co., Ltd. Israel
    Manufacturer: & nbsp
    Representation: & nbspTeva Teva Israel
    Information update date: & nbsp11.03.2016
    Illustrated instructions
      Instructions
      Up